Rani Therapeutics Secures $20M in Registered Direct Offering at $1.07/Share
RANI has more than doubled off its 52-week low of $0.387.
Summary
Rani Therapeutics has completed a $20 million registered direct offering, selling shares and pre-funded warrants at $1.07 each, providing crucial capital for the company facing a Nasdaq delisting notice.
Key Events · Financing and Capital Events · RANI
-
Capital Raise Finalized
Rani Therapeutics secured approximately $18.4 million in net proceeds from a registered direct offering of 12,476,637 shares of Class A common stock and pre-funded warrants to purchase 6,214,953 shares.
-
Pricing at Premium
The offering was priced at $1.07 per share, which is at the last reported sale price on May 22, 2026, and above the current market price of $0.9478, indicating institutional investor interest despite recent challenges.
-
Significant Dilution
The offering represents a potential dilution of approximately 13.6% of outstanding shares (18.7 million new shares on 137.4 million existing shares) and 17.16% of the company's market capitalization.
-
Addresses Liquidity Concerns
The proceeds are designated for working capital and general corporate purposes, providing a critical financial lifeline for a company that recently received a Nasdaq delisting notice and reported a material weakness in internal controls.
Analysis · RANI · Life Sciences
This filing finalizes the terms of a $20 million registered direct offering, selling common stock and pre-funded warrants at $1.07 per share. The capital raise is critical for Rani Therapeutics, which recently received a Nasdaq delisting notice due to its low stock price and has disclosed a material weakness in internal controls. While the offering is dilutive, the ability to secure significant funding at a price above the current market value ($0.9478) demonstrates institutional confidence and provides essential working capital to extend the company's operational runway and address its immediate financial challenges.
How filings like this one have moved
In the 30 days to Aug 23, 2026, 37.5% of the 3432 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RANI was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $116.5M. The 52-week trading range was $0.39 to $3.87. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.